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Rationale: To assess equivalence of twice daily (bid) budesonide/formoterol (BUD/FM)
160/4.5 mg via breath-actuated metered-dose inhaler (BAI) versus pressurized metered-dose
inhaler (pMDI).
Methods: This 12-week, double-blind, multicenter, parallel-group study, randomized adoles-
cents and adults (aged 12 years) with asthma (and 3 months daily use of inhaled corticoste-
roids) to BUD/FM BAI 2  160/4.5 mg bid, BUD/FM pMDI 2  160/4.5 mg bid, or BUD pMDI
2  160 mg bid. Inclusion required prebronchodilator forced expiratory volume in one second
(FEV1) 45 to 85% predicted, and reversibility of 12% in FEV1 (ages 12 to <18 years) or
12% and 200 mL (ages 18 years). Confirmation that 60-min postdose FEV1 response to
BUD/FM pMDI was superior to BUD pMDI was required before equivalence testing. Therapeutic
equivalence was shown by treatment effect ratio of BUD/FM BAI vs BUD/FM pMDI on 60-
min postdose FEV1 and predose FEV1 within confidence intervals (CIs) of 80e125%.
Results: Mean age of 214 randomized patients was 42.7 years. BUD/FM pMDI was superior to
BUD pMDI (60-min postdose FEV1 treatment effect ratio, 1.10; 95% CI, 1.06e1.14;
p < 0.001). Treatment effect ratios for BUD/FM BAI versus pMDI for 60-min postdose FEV1
(1.01; 95% CI, 0.97e1.05) and predose FEV1 (1.03; 95% CI, 0.99e1.08) were within predeter-
mined CIs for therapeutic equivalence. Adverse event profiles, tolerability, and patient-
reported ease of use were similar.stown.org (K.R. Murphy).
14.12.009
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
nd/4.0/).
Budesonide/formoterol via breath-actuated inhaler 171Conclusions: BUD/FM 2  160/4.5 mg bid BAI is therapeutically equivalent to BUD/FM conven-
tional pMDI. The introduction of BUD/FM BAI would expand options for delivering inhaled
corticosteroid/long-acting b2-agonist combination therapy to patients with moderate-to-
severe asthma.
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Inhaled corticosteroids (ICSs) are recommended as first-
line treatment for patients with persistent asthma, and
the addition of an inhaled long-acting b2-agonist (LABA)
can be considered to improve lung function and symptoms
in patients whose asthma is not well controlled on ICS
alone [1,2]. Combination ICS/LABAs are available as
breath-actuated dry powder inhalers (DPI) and manually-
actuated pressurized metered-dose inhalers (pMDIs).
However, to date, a breath-actuated option in a pMDI
device has not been available for the delivery of a com-
bination of ICS/LABA. For some patients, poor coordina-
tion between actuation and inhalation with use of a pMDI
can lead to dosing errors [3]. A breath-actuated pMDI
inhaler (BAI) could provide an alternative option for those
patients unable to overcome poor hand-lung coordination
[4]. This study was designed to compare the therapeutic
efficacy and safety of combined budesonide/formoterol
delivered by a BAI currently in clinical development with
those of combined budesonide/formoterol delivered by a
pMDI in patients with moderate-to-severe, symptomatic
asthma.Methods
Patients
Inclusion and exclusion criteria were designed to select
asthmatic patients aged 12 years who required medium-
to high-dose ICSs and demonstrated reversibility of airflow
obstruction with an inhaled bronchodilator after a run-in
period. Patients must have used ICSs daily for 3 months
before study entry and required consistent use of stable
daily doses of medium- to high-dose ICSs in the 30 days
before study entry. Minimum daily doses permitted were:
beclomethasone dipropionate 504 mg/d (chlorofluorocarbon
pMDI) or 160 mg/d (actuation counter pMDI), budesonide
400 mg/d, flunisolide 1000 mg/d, fluticasone 264 mg/
d (chlorofluorocarbon pMDI) or 300 mg/d (Diskus), triam-
cinolone acetonide 800 mg/d, mometasone 400 mg/d, or
ciclesonide 160 mg/d.
Patients had to have asthma symptom scores (nighttime
or daytime) of >0 on 3 of the last 7 days of the run-in
period and prebronchodilator FEV1 45% and 85% of pre-
dicted normal at baseline. Asthma symptom score is
defined as: 0, no asthma symptoms; 1, you are aware of
your asthma symptoms but you can easily tolerate the
symptoms; 2, your asthma is causing you enough discomfortto cause problems with normal activities (or with sleep); or
3, you are unable to do your normal activities (or to sleep)
because of your asthma.
To ensure reversibility with b2 agonists, patients had to
meet baseline postbronchodilator criteria (4e6 actuations
of albuterol pMDI [90 mg/inhalation] or salbutamol pMDI
[100 mg/inhalation] or after inhalation of 2.5 mg nebulized
albuterol) of a change of 12% in FEV1 from baseline for
patients aged 12 and <18 years or a change of 12% and
200 mL in FEV1 from baseline for patients aged 18 years.
In addition, patients must have demonstrated the ability to
use the BAI, pMDI, and a peak flow meter correctly.
Exclusion criteria included a history of life-threatening
asthma during the past 2 years; hospitalization for asthma-
related condition in the previous 6 months; intake of oral,
rectal, or parenteral glucocorticosteroids within 30 days
before study entry; use of any b-blocking agent, including
eye drops; required treatment with systemic steroids dur-
ing the study run-in period; or a 10 pack-year history of
smoking. Patients were also excluded if they had any sig-
nificant disease or disorder which, in the opinion of the
investigator, may increase risk to the patient or influence
the results.
The final study protocol was approved by institutional
review boards at each center. Patients provided written
informed consent and written assent as appropriate, before
study procedures were begun. The study was performed in
accordance with ethical principles based on the Declaration
of Helsinki and consistent with the International Confer-
ence on Harmonization/Good Clinical Practice and appli-
cable regulatory requirements.
Study design and treatment
This double-blind, randomized, active-controlled, multi-
center, parallel-group, 12-week study was conducted in
the United States, Bulgaria, and Hungary (NCT01360021).
A flow chart of the study design is shown in Fig. 1. The
study consisted of an enrollment visit (visit 1) and a 2-
week run-in period beginning at visit 2, during which
LABAs were discontinued, and patients were treated with
BUD actuation counter pMDI 160 mg, 2 inhalations twice
daily (bid).
Reversibility testing was performed at visit 2 (at the
start of the run-in period) and visit 3 (approximately 1e3
days before randomization), and to be eligible for the
study, patients had to be reversible on both of these oc-
casions. If a patient did not fulfill the eligibility criteria for
reversibility, one retest was allowed at either visit 2 or visit
3 (ie, only one retest total for the duration of the study).
Figure 1 Flow chart of study design. BAI, breath-actuated metered-dose inhaler; bid, twice daily; BUD, budesonide; FM, for-
moterol; pMDI, pressurized metered-dose inhaler; TC, telephone conversation.
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tients are capable of responding to beta agonists and
therefore have a potential to show a difference in the
primary objective.
Patients were randomized at visit 4 and attended the
clinic on 3 further occasions (week 3, 7, and 12), followed
by a telephone call follow-up 2 weeks later. Lung function
testing, eDiary collection, and adverse event (AE) check
occurred at each visit, and device functionality questioning
occurred at weeks 3, 7, and 12. AEs were the only data
collected on the telephone call. At visit 4, patients were
randomized to receive 1 of the 3 following double-blind
treatments shown in Fig. 1: BUD/FM BAI 160/4.5 mg (Fig. 2),
2 inhalations bid plus placebo pMDI, 2 inhalations bid; BUD/
FM pMDI 160/4.5 mg, 2 inhalations bid plus placebo BAI, 2
inhalations bid; or BUD pMDI 160 mg, 2 inhalations bid plus
placebo BAI, 2 inhalations bid. At visit 2 and visit 4, patients
were instructed on proper inhaler use, and devices were
available at each study center for training purposes and for
patients to practice. Instruction and practice also occurred
prior to dispensing blinded study drug at visit 4. Confirma-
tion of proper device use was accomplished via patient
response in their eDiary to device functionality questions.
Additionally, for further confirmation at return visits, the
investigator or staff asked the patient if device instructions
were being followed and provided additional training if
required.Figure 2 Schematic representation of the breath-actuated
inhaler device. Trigger flow rate is less than 28 L/min. Data
on file [9].Concomitant medications
Patients were allowed the use of a short-acting b2-agonist
(SABA) as rescue medication throughout the study including
enrollment, run-in, and treatment periods; albuterol pMDI
(90 mg/inhalation)/salbutamol pMDI (100 mg/inhalation)
were provided by the study site as rescue medication.
Medications not allowed during the study included paren-
teral, oral, or rectal glucocorticosteroids; leukotrieneantagonists; inhaled disodium cromoglycate; inhaled
nedocromil sodium or 5-lipoxygenase inhibitors; methyl-
xanthines; inhaled anticholinergics; any monoclonal or
polyclonal antibody therapy taken for any reason; or
CYP3A4 inhibitors (eg, ketoconazole).
Use of the following medications was allowed during the
study: mucolytics and expectorants not containing bron-
chodilators; antihistamines (other than terfenadine, aste-
mizole, mizolastine); allergen-specific immunotherapy if
the patient had been on a maintenance regimen for 3
months before visit 1 and remained on a maintenance
regimen during the study; topical, nasal, and/or ocular
formulations of glucocorticosteroids; topical, nasal and/or
ocular disodium cromoglycate and/or nedocromil sodium.
Other medication, which was considered necessary for the
patient’s safety and well-being, could be administered at
the discretion of the investigator(s).
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The primary objective of this study was to evaluate ther-
apeutic equivalence of BUD/FM delivered by BAI with BUD/
FM delivered by pMDI. The primary efficacy end points for
assessing therapeutic equivalence were comparison of the
effects of BUD/FM BAI with BUD/FM pMDI on FEV1 at
60 min postdose and FEV1 predose. To ensure that any po-
tential differences in efficacy could be detected, it was
prespecified that BUD/FM pMDI was superior to BUD pMDI on
60-min postdose FEV1. Subsequent assessment of thera-
peutic equivalence would be established if the 95% confi-
dence interval (CI) limits for the ratio of treatment effects
of BUD/FM delivered by BAI versus pMDI was contained
within the equivalence limits of 80e125% [5].
Secondary efficacy end points collected by means of an
electronic diary (eDiary) included mean change from
baseline for the overall treatment period for morning and
evening peak expiratory flow (PEF), daytime and nighttime
and total asthma symptom scores, awakening-free nights
(nights without awakening due to asthma symptoms), day-
time and nighttime rescue medication use, and symptom-
free days.
A secondary objective was to assess patient-reported
functionality of the 2 devices. Patients used the eDiary to
complete an end-of-study questionnaire through which the
patient-reported ease of use of each device was evaluated.
This questionnaire contained 2 questions (‘How easy was it
to use the inhaler?’ and ‘How easy is it to determine when
you will run out of medicine [from the inhaler]?’). Each
question was scored on a 7-point scale, with options ranging
from ‘Extremely easy’ to ‘Extremely difficult’: (0,
extremely easy; 1, very easy; 2, somewhat easy; 3, neither
easy nor difficult; 4, somewhat difficult; 5, very difficult; 6,
extremely difficult).
Safety evaluations
The safety profile of BUD/FM delivered by pMDI or BAI was
assessed by comparing the nature, intensity, and severity of
AEs occurring in each treatment group.Figure 3 Patient disposition. BAI, breath-actuated metered-dos
pMDI, pressurized metered-dose inhaler.Statistical analyses
To assess the therapeutic equivalence of newly developed
BUD/FM BAI device with the marketed BUD/FM pMDI de-
vice, a step-down procedure was used to address multi-
plicity. First, superiority needed to be demonstrated for
BUD/FM pMDI versus BUD pMDI for the difference in post-
dose FEV1 with a statistical significance level of 5%. If this
requirement was met, then the 95% CI for the ratio of
treatment effects was to be used to assess therapeutic
equivalence of BUD/FM pMDI versus BUD/FM BAI. The pri-
mary variable for this comparison was the mean of the
postdose FEV1 measurements obtained during treatment
period (visits 4e7) expressed as ratio of the predose FEV1 at
randomization (visit 4) to create the treatment:baseline
ratio. The logarithm of this value was used for analysis using
the analysis of covariance (ANCOVA) model with the fixed
factors treatment and country, and the logarithm of the
predose FEV1 at randomization as a covariate.
If the superiority condition was met in comparison to BUD
pMDI, a 95% CI for the ratio of treatment effects contained
within equivalence limits of 80e125% [5] for FEV1
60 min postdose and FEV1 predose would establish thera-
peutic equivalence of BUD/FM BAI and BUD/FM pMDI. The
model used to estimate the ratio of treatment effects was
the same for predose FEV1 as for postdose FEV1 described
above (ie, a multiplicative ANCOVA with the treatment and
country as factors and baseline predose FEV1 as a covariate).
For all variables other than these, pair-wise comparisons
were made and nominal (unadjusted for multiplicity) p
values are reported. All hypothesis testing was conducted
using 2-sided tests. The p values were rounded to 3 decimal




Patient disposition is shown in Fig. 3, and the key de-
mographics of the randomized population are shown ine inhaler; bid, twice daily; BUD, budesonide; FM, formoterol;
Table 1 Patient demographics and baseline asthma characteristics.
Characteristic BUD/FM BAI (n Z 71) BUD/FM pMDI (n Z 71) BUD pMDI (n Z 72)
Sex, n (%)
Male 34 (47.9) 24 (33.8) 37 (51.4)
Female 37 (52.1) 47 (66.2) 35 (48.6)
Age, y 42.8 (16.2) 42.6 (16.9) 42.7 (14.4)
Age group, n (%)
12 to <18 y 6 (8.5) 8 (11.3) 7 (9.7)
18 to <65 y 60 (84.5) 56 (78.9) 62 (86.1)
65 to <75 y 4 (5.6) 4 (5.6) 2 (2.8)
75 y 1 (1.4) 3 (4.2) 1 (1.4)
Race, n (%)
White 57 (80.3) 63 (88.7) 57 (79.2)
Black/African American 9 (12.7) 7 (9.9) 11 (15.3)
Asian 4 (5.6) 1 (1.4) 1 (1.4)
Native Hawaiian or Pacific Islander 0 (0) 0 (0) 1 (1.4)
Other 1 (1.4) 0 (0.0) 2 (2.8)
ICS dose at entry, mg/d 537.3 (219.9) 561.1 (193.8) 507.7 (212.2)
Years since asthma diagnosis
Mean (SD) 24.3 (14.9) 24.1 (15.1) 24.4 (15.2)
Range 1e68 1e60 1e59
Predose FEV1, L
a 2.17 (0.61) 1.97 (0.52) 2.19 (0.54)
Baseline FEV1,L
b 2.18 (0.63) 2.04 (0.57) 2.18 (0.56)
Morning PEF, L/minc 357.95 (100.59) 335.70 (102.99) 360.46 (103.09)
Evening PEF, L/minc 364.61 (103.62) 347.86 (110.80) 367.64 (102.73)
Daily rescue medication use (inh/d)c 2.55 (2.48) 2.19 (1.75) 2.65 (2.36)
Asthma total symptom scorec 2.04 (0.98) 1.92 (0.72) 2.12 (0.88)
Awakening-free nights, %c 78.54 (28.97) 78.76 (29.76) 81.59 (25.32)
Values shown are mean (SD) unless otherwise noted.
BAI, breath-actuated inhaler; BUD, budesonide; FM, formoterol; ICS, inhaled corticosteroid; inh/d, inhalations per day; pMDI, pres-
surized metered-dose inhaler; PEF, peak expiratory flow; SD, standard deviation.
a Predose is defined as the mean value obtained at visit 2 (run-in period).
b Baseline is defined as the mean obtained at visit 4 (randomization).
c Basline is defined as the mean of all values obtained during the run-in period.
174 K.R. Murphy et al.Table 1. In total, 214 patients with a mean age of 42.7
years and a mean time from asthma diagnosis of 24  15
years were randomized, of whom 213 received 1 dose of
study drug. One patient was randomized in error in the
randomization system while the investigator intended to
mark the patient as a screen failure. The subject was
immediately discontinued from the study before receiving
study treatment and was therefore excluded from efficacy
and safety analyses. This cohort of 213 patients formed
the full analysis set for efficacy parameters and the safety
analysis set.
Before study entry, 152 of 213 patients (71.4%) were using
combination therapy of b2-agonists plus other drugs, with
fluticasone plus salmeterol being the most common (nZ 86;
40.4%). Inhaled glucocorticoids were used by 211 patients
(99.1%) before run-in, with fluticasone being the most
common (nZ 105; 49.3%). Two patients receiving ICS/LABA
combination therapy before study entry were not switched
to monocomponent ICS before run-in but were subsequently
included in the study. Selective SABAs were used by 210
patients (98.6%), with inhaled albuterol or salbutamol being
the most common (n Z 190; 89.2%). Other prestudy drugs
for asthma included leukotriene receptor antagonists
(n Z 18; 8.5%), xanthines (n Z 5; 2.3%), anticholinergics
(n Z 1; 0.5%), and allergen extracts (n Z 1; 0.5%).Study medication adherence, which was defined as the
percentage of the expected number of medication intakes
recorded in the eDiary, as self-reported on a daily basis,
was generally good and similar across groups (87.9%, 87.1%,
and 85.4% for BUD/FM BAI, BUD/FM pMDI, and BUD pMDI,
respectively).Efficacy
The geometric ratio of the mean change from baseline in
postdose FEV1 over time for the 3 treatment groups is
shown in Fig. 4. Table 2 shows the postdose FEV1 treatment
comparisons, for which there was a statistically significant
difference between BUD/FM pMDI and BUD pMDI
(p < 0.001). Therefore, the required superiority of BUD/FM
pMDI versus BUD pMDI was demonstrated. For postdose
FEV1, the ratio of the treatment effects for the BUD/FM BAI
and the pMDI was estimated to be 1.01, with a CI of
0.97e1.05, within the predetermined limits, indicating
therapeutic equivalence (Table 2).
The mean change in predose FEV1 over time for the 3
treatment groups is shown in Fig. 5, and Table 2 shows the
treatment comparisons for predose FEV1. The predose FEV1
ratio of the treatment effects for BUD/FM BAI and BUD/FM
Figure 4 Ratio of geometric mean of treatment to baseline: 60-min postdose FEV1 (L) over 12 weeks and treatment average.
Ratio is calculated as geometric mean of treatment average divided by geometric mean at baseline. Treatment average is defined
as the mean of all available variables after randomization. Baseline for postdose FEV1 is predose FEV1 at visit 4 (week 0). BAI,
breath-actuated metered-dose inhaler; BUD, budesonide; FEV1, forced expiratory volume in 1 s; FM, formoterol; pMDI, pressurized
metered-dose inhaler; Trt. Avg., treatment average.
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confirming therapeutic equivalence.Secondary outcomes
The mean change from baseline over time in morning and
evening PEF for the 3 treatment groups is shown in Fig. 6.Table 2 Treatment group comparisons for postdose and
predose FEV1 (L).
Treatment Ratio of treatment to baseline
LS mean
(CV%)a
95% CI p Value
Postdose FEV1
BUD/FM BAI vs BUD pMDI 1.11 (1.99) 1.07e1.16 <0.001
BUD/FM pMDI vs BUD pMDI 1.10 (2.00) 1.06e1.14 <0.001
BUD/FM BAI vs
BUD/FM pMDI
1.01 (1.99) 0.97e1.05 0.547
Predose FEV1
BUD/FM BAI vs BUD pMDI 1.06 (2.21) 1.02e1.11 0.007
BUD/FM pMDI vs BUD pMDI 1.03 (2.22) 0.98e1.07 0.238
BUD/FM BAI vs
BUD/FM pMDI
1.03 (2.22) 0.99e1.08 0.131
ANCOVA, analysis of covariance; BAI, breath-actuated metered-
dose inhaler; BUD, budesonide; CI, confidence interval; CV,
coefficient of variation; FEV1, forced expiratory volume in 1 s;
FM, formoterol; LS, least squares; pMDI, pressurized metered-
dose inhaler.
a ANCOVA model on the log-transformed outcome variable
with treatment and country as factor, and log-transformed
baseline FEV1 (predose) as covariate. LS mean is obtained by
back-transformation of the LS mean resulting from ANCOVA of
log-transformed data.The degree of improvement in morning and evening PEF
was similar for BUD/FM delivered by either BAI or pMDI
(nominal pZ 0.825 and 0.810 for morning and evening PEF,
respectively). In contrast, BUD/FM delivered by both de-
vices resulted in improved morning and evening PEF versus
BUD pMDI (Table 3); Table 3 also shows the other secondary
efficacy end points unadjusted for multiplicity. The only
nominal p value favoring BUD/FM pMDI over BAI was for
awakening-free nights with the difference p < 0.05 (un-
adjusted p Z 0.025). All secondary end points demon-
strated numerical superiority for both BUD/FM BAI and pMDI
versus BUD pMDI. Nominal p values <0.05 were observed for
all BUD/FM BAI versus BUD pMDI comparisons except
awakening-free nights, rescue medication use, and
symptom-free days (Table 3).
Based on eDiary answers twice daily to the yes/no
question “Did the inhaler deliver a puff every time you
inhaled today?”, patients indicated delivery of the dose on
99.2% and 99.4% of occasions for BUD/FM BAI and pMDI,
respectively. For both BUD/FM BAI and BUD/FM pMDI, a
large majority of patients (86.3% and 88.2%, respectively)
reported the ease of use to be ‘extremely easy’ or ‘very
easy’. The percentage of patients reporting the ease of
determining when the medication will run out as
‘extremely easy’ or ‘very easy’ was numerically greater for
BUD/FM BAI than the pMDI device (87.7% and 73.9%,
respectively).
Safety
Overall, AEs were experienced by 21 (29.6%), 24 (33.8%),
and 19 (26.8%) of patients in the BUD/FM BAI, BUD/FM
pMDI, and BUD pMDI groups, respectively. However, only 1
serious AE occurred, a case of appendicitis in the BUD/FM
pMDI group, and this was not considered related to
treatment.
Figure 5 Ratio of geometric mean of treatment to baseline: predose FEV1 (L) over 12 weeks and treatment average. The ratio is
calculated as geometric mean of treatment average divided by geometric mean at baseline. Treatment average is defined as the
mean of all available variables after randomization. Baseline is defined as the last predose value before first dose of randomized
therapy at visit 4 (week 0). BAI, breath-actuated metered-dose inhaler; BUD, budesonide; FEV1, forced expiratory volume in 1 s;
FM, formoterol; pMDI, pressurized metered-dose inhaler; Trt. Avg., treatment average.
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piratory tract infections, asthma, bronchitis, bacterial
upper respiratory tract infection, nasopharyngitis, oral
candidiasis, and enteritis. Viral upper respiratory tract in-
fections occurred in 2 (2.8%), 5 (7.0%), and 3 (4.2%) of pa-
tients in the BUD/FM BAI, BUD/FM pMDI, and BUD pMDI
groups, respectively. Asthma was listed as an AE in 1 (1.4%),
2 (2.8%), and 3 (4.2%) of the patients in the BUD/FM BAI,
BUD/FM pMDI, and BUD pMDI groups, respectively. The
corresponding rates for bronchitis were 1 (1.4%), 3 (4.2%),
and 0 (0.0%). Other AEs occurred in 2 patients in
any group.
Eight patients discontinued treatment because of AEs, of
whom 5 discontinued because of asthma exacerbations (1,
1, and 3 patients in the BUD/FM BAI, BUD/FM pMDI, and BUDFigure 6 Self-reported morning (A) and evening (B) PEF. Baseli
metered-dose inhaler; BUD, budesonide; FEV1, forced expiratory
pMDI, pressurized metered-dose inhaler.pMDI groups, respectively). Other causes of discontinuation
were gout (BUD/FM BAI), eczema and gingival pain (BUD/FM
pMDI), and bacterial upper respiratory tract infection
(BUD pMDI).Discussion
The aim of this study was to evaluate the therapeutic
equivalence of a BAI and conventional pMDI device
delivering the BUD/FM combination. For both postdose
and predose FEV1, the CIs for the ratio of the treatment
effects for BUD/FM BAI and pMDI were within the 95% CI
equivalence limits of 80e125%, demonstrating therapeu-
tic equivalence. All secondary end points providene is the mean of run-in period values. BAI, breath-actuated
volume in 1 s; FM, formoterol; PEF, peak expiratory flow;
Table 3 Treatment group differences for secondary end points.
Treatment ANCOVA summary treatment comparisons
LS mean (SE) 95% CI p Valuea
Morning PEF (L/min)
BUD/FM BAI minus BUD pMDI 35.01 (6.72) 21.77 to 48.26 <0.001
BUD/FM pMDI minus BUD pMDI 33.52 (6.80) 20.11 to 46.93 <0.001
BUD/FM BAI minus BUD/FM pMDI 1.49 (6.75) 11.81 to 14.80 0.825
Evening PEF (L/min)
BUD/FM BAI minus BUD pMDI 33.73 (6.14) 21.62 to 45.84 <0.001
BUD/FM pMDI minus BUD pMDI 32.25 (6.21) 20.01 to 44.49 <0.001
BUD/FM BAI minus BUD/FM pMDI 1.48 (6.15) 10.66 to 13.61 0.810
Asthma total symptom score
BUD/FM BAI minus BUD pMDI 0.27 (0.11) 0.50 to 0.05 0.018
BUD/FM pMDI minus BUD pMDI 0.40 (0.12) 0.63 to 0.17 <0.001
BUD/FM BAI minus BUD/FM pMDI 0.13 (0.11) 0.10 to 0.35 0.272
Awakening-free nights (%)
BUD/FM BAI minus BUD pMDI 1.18 (2.70) 4.14 to 6.50 0.662
BUD/FM pMDI minus BUD pMDI 7.28 (2.7) 1.96 to 12.60 0.008
BUD/FM BAI minus BUD/FM pMDI 6.10 (2.69) 11.41 to 0.79 0.025
Daily rescue medication use (inhalations/24 h)
BUD/FM BAI vs BUD pMDI 0.44 (0.23) 0.89 to 0.00 0.052
BUD/FM pMDI vs BUD pMDI 0.70 (0.23) 1.15 to 0.25 0.002
BUD/FM BAI vs BUD/FM pMDI 0.26 (0.23) 0.19 to 0.71 0.258
Symptom-free days (%)
BUD/FM BAI vs BUD pMDI 5.63 (4.29) 2.82 to 14.08 0.190
BUD/FM pMDI vs BUD pMDI 11.70 (4.28) 3.27 to 20.14 0.007
BUD/FM BAI vs BUD/FM pMDI 6.07 (4.25) 14.45 to 2.31 0.155
Rescue-free days (%)
BUD/FM BAI vs BUD pMDI 11.20 (4.66) 2.00 to 20.39 0.017
BUD/FM pMDI vs BUD pMDI 19.02 (4.66) 9.83 to 28.21 <0.001
BUD/FM BAI vs BUD/FM pMDI 7.82 (4.65) 17.0 to 1.35 0.094
ANCOVA includes treatment and country as a factor and baseline value as covariate.
ANCOVA, analysis of covariance; BAI, breath-actuated metered-dose inhaler; BUD, budesonide; CI, confidence interval; FM, formoterol;
LS, least squares; PEF, peak expiratory flow; pMDI, pressurized metered-dose inhaler; SE, standard error.
a Nominal p values reported, unadjusted for multiplicity.
Budesonide/formoterol via breath-actuated inhaler 177supporting evidence for the equivalent efficacy of BUD/
FM administered by BAI or pMDI except for awakening-
free nights. However, the baseline level of awakening-
free nights was relatively high for all groups (79e82%)
with accordingly small percent changes at study end
(2.5e8.6%) observed across all groups, and there was no
statistically significant difference in either night time
symptoms or night time rescue inhaler use between BUD/
FM BAI and pMDI.
Both primary (postdose FEV1) and secondary (morning
and evening PEF) pulmonary function end points are
consistent with the superior efficacy of BUD/FM versus BUD
alone. Figs. 4e6 show that the improvements in most pul-
monary function variables were sustained across the study
period. These results are in line with findings of 2 previous
12-week trials in which postdose FEV1 and morning and
evening PEF were significantly improved with BUD/FM pMDI
versus BUD alone [6,7]. Similarly, the effects of BUD/FM
delivered by either device were numerically superior to
BUD alone for all patient-reported outcomes. As withpulmonary function improvements, these results are
consistent with those of previous studies of BUD/FM and
BUD alone [6e8].
Statistical significance of BUD/FM versus BUD alone was
observed for postdose FEV1, demonstrating the ability to
discriminate differences in efficacy. Improvement in pre-
dose FEV1 in response to BUD/FM pMDI versus BUD alone
was numerically better, but not statistically significant in
our study (Table 2). The magnitude of the response in
predose FEV1 observed in the present study was similar to
that noted in previously published studies [6e8]. The lack
of statistical significance for the average change in predose
FEV1 during the treatment period between BUD/FM pMDI
and BUD pMDI in the present study could be explained by
differences in the dose of medication employed [7,8] and
differences in the population studied [7]. Moreover, unlike
the previous studies [6e8], our study was not statistically
powered to assess differences in average predose FEV1
between BUD/FM pMDI and BUD pMDI as a primary outcome
variable.
178 K.R. Murphy et al.The BAI device is similar to the pMDI device in many
ways including identical drug formulations, canister, valve
type, and stem orifice, as well as very similar mouth-
pieces. The basic mode of operation is also the same be-
tween the pMDI and BAI devices: a force is applied to the
canister base, which depresses the metering valve and
releases a dose. For a pMDI inhaler, the force is created
when the patient presses down on the top of the inhaler
while inhaling. For the BAI device, a patient’s inhalation
triggers a spring, which applies the force for release of the
medication (therefore eliminating the need to coordinate
inhalation with manual actuation). The trigger inspiratory
flow rate is less than 28 L/min [9] which almost all pa-
tients can achieve [10]. The BAI was a new device to all
patients in the study, and results from the patient func-
tionality study indicated that the ease of use was similar
to the pMDI device.
Patients in both the pMDI and BAI groups reported that
their device delivered a dose on greater than 99% of oc-
casions. However, there were differences in the ease of
identifying when medication was running out. More pa-
tients using the BAI device (55%) than the pMDI device (41%)
found it ‘extremely easy,’ which may be because of the
different dose counters used on each device. The pMDI
device has a fuel-gauge-style dose counter, with an arrow
pointing to a circular gauge ranging from 120 to 0, with
demarcations every 5 actuations and numerals every 10
actuations. The BAI device has a mechanical digital counter
that displays the exact number of actuations remaining,
starting at 120 and counting down in increments of 1 after
each actuation.
The safety profile of both devices was consistent with
that of previously published results [6,7]. Noonan et al. [6]
compared BUD/FM pMDI with BUD pMDI, FM DPI, BUD plus
FM in separate inhalers (BUD pMDI þ FM DPI), and placebo
in moderate to severe asthma patients. As with the pre-
sent study, all treatments were well tolerated, and most
AEs were mild to moderate [6]. In the Noonan study, the
incidence of oral candidiasis in the BUD/FM pMDI group
was higher than that in other groups [6]. However, in the
present study, oral candidiasis was experienced by only 1
patient in each patient group.
Corren et al. [7] also reported safety results from a 12-
week trial of BUD/FM pMDI versus BUD pMDI and FM DPI in
patients with mild to moderate asthma. As with the present
study, the treatments were well tolerated, and most AEs
were of mild or moderate intensity [7]. In the Corren study
[7], the most common AE possibly related to BUD/FM pMDI
treatment was cough (2 patients; 1.6%), with single (0.8%)
additional cases of headache, pharyngolaryngeal pain,
tremor, and jitteriness. In the present study, headache
occurred in just 1 patient (1.4%) in the BUD/FM BAI group
and in none of the patients receiving BUD/FM pMDI. The
only case of cough was reported in the BUD/FM BAI group,
and 1 patient in each of the BUD/FM groups experienced
tremor.Conclusion
BUD/FM 160/4.5 mg  2 inhalations bid administered by a
BAI device is therapeutically equivalent to BUD/FM 160/4.5 mg  2 inhalations bid delivered by a conventional
pMDI based on both predose and postdose FEV1.
Furthermore, no difference in safety profiles was identi-
fied. The introduction of BUD/FM BAI would represent an
expansion of options to help tailor effective ICS/LABA
combination therapy for patients with moderate-to-
severe asthma.Funding
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